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Neurodegeneration in Alzheimer’s disease (AD) is thought
to be initiated by a cascade of neurotoxic events that
include oxidative stress, brain iron dysregulation, glutamate
excitotoxicity,nitricoxide,inﬂammatoryprocess,neurotoxic
processing resulting from misfolding, and aggregation of
Abeta peptide, as a possible consequence of the demise of
ubiquitin-proteasome system (UPS) which is demonstrated
neurochemically and by transcriptomics and proteomic
proﬁling. AD is beneﬁtted from the symptomatic eﬀects of
cholinesterase inhibitors and glutamate antagonist (meman-
tine),whichactonasinglemoleculartarget.Suchdrugshave
limited symptomatic activities, and current pharmacological
approaches have severe limitations in their ability to be neu-
roprotective and to modify the course of the disease, oﬀering
incomplete and transient beneﬁt to patients. Yet in labora-
tory and animal models, a number of drugs have demon-
strated the ability to be neuroprotective, but in clinical trials,
they have failed as a form of symptomatic treatment and
disease modiﬁcation. This situation is not diﬀerent from that
of Parkinson’s disease or amyotrophic lateral sclerosis, where
the same problems exist. There are a number of valid reasons
why we have failed to alter the course of these progressive
neurodegenerative disorders. First and foremost, the models
employed in vitro and in vivo are not true representations of
complexdiseaseasseeninman.Mostoftheeﬀorthasbeenin
thedirectionofpreventingtheformationandoverexpression
of Abeta peptide in transgenic mice expressing Abeta peptide
and plaques. Yet in these animals, there is no process of
neurodegeneration. Yet one must question whether the dis-
easeisadisorderofAbeta-peptide-inducedplaqueformation
resulting in the cognitive decline or if other processes are
involved. The hope is that the newlydeveloped rat transgenic
model, which emulates many features of AD, will advance
the pathological understanding of the disease and may
lead to the development of new therapeutic strategies. The
complex pathology of AD pathways includes changes in
gene expression, protein metabolisms, response of receptors,
level of neurotransmitters, activity of kinase, and signaling
pathways. The most important events in neuroprotection
andneuroregenerationaretheselectionofdrugsthatinclude
synthetic products,naturalproducts,amyloid synthesis, hor-
monal balance, and nanoparticles intended for a variety of
biochemicaltargetssuchasoxidative stress.Thisspecialissue
provides a new knowledge based on therapeutic candidates
designed to act on multiple neural and biochemical targets
involved in the neurodegenerative process and to possess
neuroprotective and neurorestorative activities.
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